Background
The immunogenicity of adenovirus serotype 5 (Ad5) vectors is suppressed by pre-existing neutralizing antibodies (NAbs) that are directed primarily against the hexon hypervariable regions (HVRs). We previously reported that replacing all 7 HVRs of the Ad5 hexon protein with those from the rare serotype Ad48 resulted in a chimeric Ad5HVR48(1-7) vector that evaded pre-existing immunity in preclinical studies.
Methods
An intermediate Ad5HVR48(1-3) vector was constructed by replacing only the first three HVRs of Ad5 with those of Ad48. C57/BL6 mice, either naïve or preimmunized twice with 10 10 vp of Ad5Empty, were immunized with 10 9 vp of Ad5, Ad5HVR48(1-3) or Ad5HVR48(1-7) vectors expressing SIV-Gag. Gag-specific CD8+ T cell responses were measured by tetramer binding, ELISPOT and ICS assays following immunization. Human and murine sera were also assessed for neutralizing antibody responses against Ad5, Ad5HVR48(1-3), Ad5HVR48(1-7), and Ad48.
Results
Ad5, Ad5HVR48(1-3), and Ad5HVR48(1-7) vectors expressing SIV-Gag proved comparably immunogenic in mice by tetramer, ELISPOT, and ICS assays. In the presence of Ad5-specific pre-existing immunity, however, the immunogenicity of Ad5 and Ad5HVR48(1-3) vectors was abrogated and only Ad5HVR48(1-7) was immunogenic. NAb titers in Ad5-vaccinated mice as well as in humans from sub-Saharan Africa were stratified as follows: Ad5 >Ad5HVR48(1-3) > Ad5HVR48(1-7) > Ad48.
Conclusion
The serology studies indicate that a fraction of Ad5-specific NAbs are directed against HVR 1-3. However, the Ad5HVR48(1-3) vector was unable to evade Ad5-specific NAbs in vivo. These data indicate that HVR 4-7 contain key Ad5-specific NAb epitopes.
